RxDoctor Payments Data

Gina Fernando

Psychiatric/Mental Health · Rockford, ILNPI 1750907861

Payments from drug & device makers

$1,567in general payments, 2019–2025

Across 70 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$401
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$138
  • Alkermes, Inc.$131
  • Supernus Pharmaceuticals, Inc.$125
  • Otsuka America Pharmaceutical, Inc.$120
  • Teva Pharmaceuticals USA, Inc.$109
  • plus $543 from 14 others

What the payments were for

  • Food & beverage$1,567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,567 in reported general payments places this provider in the 75th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$3,879
Medicare patients
11
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$62,760
MounjaroTirzepatide24$28,533
TrulicityDulaglutide26$25,082
OzempicSemaglutide25$23,781
EliquisApixaban24$23,229
RybelsusSemaglutide17$21,193
XareltoRivaroxaban12$15,432
Breo ElliptaFluticasone/Vilanterol21$11,510
FarxigaDapagliflozin Propanediol11$8,835
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$8,514
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,087
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$5,083
SymbicortBudesonide/Formoterol Fumarate15$4,656
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$62,76056 claims
Lilly USA, LLCMounjaro, Trulicity$47$53,61450 claims
Novo NordiskOzempic, Rybelsus$80$44,97542 claims
Johnson & JohnsonXarelto$39$15,43212 claims
AstraZenecaFarxiga, Symbicort$24$13,49126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →